Welcome to The Intolerant Lefty Blog! I started this blog of commentary and analysis on some of the most pressing issues of our time that just happen to effect me. From politics to mental health, addiction to psychedelics, I provide my perspective, backed up by facts.
Friday, November 4, 2022
The Foul Play of Executives when it comes to Psychedelic Stocks
The Foul Play of Psychedelic Stocks
Blog Introduction: It's no secret that big money is interested in psychedelics. After all, the potential to heal disorders and addictions is huge, and there's a lot of money to be made in the industry. However, recent reports of foul play among the top players when it comes to psychedelic stocks have me concerned. I've been investing in psychedelic research for the last six years, and I've seen firsthand how quickly you can make a lot of money and I have seen just how quickly the bottom can fall out when companies are more interested in making a quick buck than in delivering on their promises.
For the last six years, I have been investing in psychedelic research. I believed in the science, and I still do. But lately, I've been feeling uneasy about the state of affairs when it comes to the top players in the industry. Compass Pathways and Mind Meds are a mess and there have been reports of possible foul play. I'm concerned that this will be bad for psychedelic science as a whole not to mention my personal losses.
The Bottom Falls Out
I first got interested in psychedelic stocks back in 2014, when a friend told me about a company called Compass Pathways that was working on developing treatments for mental health disorders using psychedelics. I did some research and decided to invest, and I was rewarded handsomely over the next few years as Compass Pathways' stock price rose. In 2019 and 2020, I did very well for myself. But then the bottom seems to have fallen out.
Recent reports suggest that Compass Pathways is more interested in making a quick buck than in developing effective treatments. The company has been accused of using investor money to fund lavish lifestyle choices for its CEO, rather than reinvesting it into research and development. Additionally, there are reports of possible foul play among the top executives at Mind Meds, another major player in the psychedelic stock market. Another company that I am invested in as soon as they went public, and I did very well for the first 2 years and even though its tanked over the last year I am still holding because I believe in the science. These reports have me concerned that investors are being ripped off and that the science behind psychedelics will suffer as a result.
What's Going On?
Psychedelics are having a moment. They're being touted as a potential cure for everything from depression to addiction. And there's a lot of money to be made in this new industry. That's why some of the top players are Venture capitalists who are more interested in making a quick buck than they are in helping people heal.
This is not to say that all Venture capitalists are bad people. But when it comes to Compass Pathways and Mind Meds, I'm starting to wonder if they're more interested in ripping off investors than they are in actually doing good science. There have been reports of possible foul play and I'm not surprised when you look at the people involved. These companies are a mess and I'm worried that it's going to reflect poorly on psychedelic science as a whole.
What's Going on With Compass Pathways and Mind Meds?
Compass Pathways and Mind Meds are two of the top players in the psychedelics industry, but they're both a mess right now and they are not alone. There have been reports of possible foul play, and I'm not surprised when you look at the money people involved in starting these two companies. Although my values and politics didn't align with these venture capitalists, I was and am still convinced of the science behind psychedelics and mental health. I believe in their potential to heal disorders and addictions, which would obviously turn into a very big industry with vast sums of money being spent and made. That's why the money people are involved.
But it seems like they're more interested in making a quick buck than anything else. And that's not good for anyone – investors, patients, or even the psychedelic industry as a whole. If these companies rip off investors, it'll be bad for everyone involved. Let's hope that isn't what is happening.
I'm still convinced of the science behind psychedelics and mental health, but I'm concerned that the bad actors in the industry are going to cause investors to lose faith in the potential of these treatments. I believe in psychedelics, and I believe in the science behind them. But I have to ask is the industry more interested in making money than they are in helping people heal? If this continues, it will be bad for psychedelic science as a whole. I'm concerned because I've been investing in psychedelic research for years, and I believe in the potential of psychedelics to help people heal from mental illness. But it seems like the money people are only interested in making a quick buck, and that could be bad for everyone involved – investors, patients, or even the psychedelic industry as a whole. Let's hope that doesn't happen.